Table of Contents
What changed
Revenue rose 10.2% to NZ$4.3m from NZ$3.9m in HY22, with commentary citing a European sales rebound and the start of Probi sales offsetting weak USA sales and Canadian stock-return costs. The PBT loss narrowed only marginally to NZ$1.7m from NZ$1.8m (6.1%), and because tax was nil in both periods, NPAT moved the same amount. Operating cash flow swung to a NZ$0.4m inflow from effectively breakeven (NZ$0.004m) in HY22. Despite that, cash fell to NZ$8.8m from NZ$9.6m at HY22. Equity contracted 19.5% to NZ$10.5m as accumulated losses eroded the capital base, while gross borrowings remained immaterial at NZ$0.01m, leaving the group firmly net cash.
What matters
- Revenue growth has not translated to operating leverage. A 10.2% top-line gain delivered only NZ$0.1m of loss reduction, implying fixed-cost absorption is weak and the path to breakeven remains distant at current revenue scale.
- Cash improvement is working-capital-led, not earnings-led. Trade debtors fell 56.7% to NZ$0.5m and inventories fell 39.0% to NZ$0.8m; receivable days compressed from 55.0 to 21.6 and inventory days from 58.5 to 32.4. These releases, not profitability, explain the NZ$0.35m operating inflow.
- Annualised run-rate is below FY22. Doubling HY23 gives NZ$8.6m against FY22 revenue of NZ$9.0m, a 4.3% shortfall, even though FY22 was second-half weighted (HY22 was only 43.4% of the full year). The HY23 step-up is therefore weaker than the FY22 seasonality pattern would have implied.
Expectations
No numeric targets, forward-work balance, or formal guidance were disclosed. FY22 seasonality was second-half weighted on revenue but first-half weighted on losses (HY22 carried 66.4% of the full-year loss, with an implied NZ$0.9m H2 loss). Applied mechanically, that pattern would suggest a softer second-half revenue requirement and a potentially narrower H2 loss, but HY23 revenue of NZ$4.3m already tracks below the implied HY22-shape 43.4% share of a flat FY22. The release supports a claim of year-on-year top-line recovery; it does not support a claim of being on track to materially exceed FY22 revenue or to reach breakeven.
Quality of result
The earnings improvement is small and clean of tax distortion (both periods carry a nil tax charge), so the 6.1% PBT and NPAT narrowing reads as a genuine, if modest, operating improvement. The cash result is of materially lower quality: the NZ$0.35m inflow was delivered alongside a NZ$0.7m fall in receivables and a NZ$0.5m drop in inventory, both of which are one-time balance-sheet releases that cannot repeat at the same magnitude. EBITDA was not disclosed for either half, so cash conversion against an operating-earnings benchmark cannot be tested. Equity fell NZ$2.5m year-on-year and ROE weakened to -16.1% from -13.8%, consistent with continued cash burn against a shrinking equity base.
Unresolved
- What portion of the revenue uplift is Probi-related versus underlying core demand, and is Probi revenue incremental or pass-through?
- What was the gross margin impact of the Canadian stock-return costs, and is that drag now complete?
- With inventory and receivables already run down hard, where does further working-capital support for cash come from in H2?
- At the current loss rate of roughly NZ$1.7m per half, how many halves of runway does the NZ$8.8m cash balance represent before a capital event becomes a live question?
- No gross margin, capex, segment, or customer-concentration disclosure was provided, so this briefing cannot assess unit economics, reinvestment intensity, or revenue concentration risk.
Key metrics
| Metric | HY23 | HY22 | Change |
|---|---|---|---|
| Revenue | $4.3m | $3.9m | +10.2% ↑ |
| Net profit after tax | −$1.7m | −$1.8m | +6.1% ↑ |
| Net cash inflow from operating activities | $0.4m | $0.0m | +8675.0% ↑ |
| Declared dividend per share | 0.0c | — | — |
| Total assets | $12.4m | $15.0m | -17.1% ↓ |
Reference: annolyse.ai/briefings/blt-hy23
Analytical metrics
| Metric | HY23 | HY22 | Context |
|---|---|---|---|
| Debtor days | 21.6 | 55.0 | -33.4 days |
| Inventory days | 32.4 | 58.5 | -26.1 days |
| Trade debtors | $0.5m | $1.2m | −$0.7m |
| Net debt | −$8.7m | −$9.5m | +$0.8m |
| Gross borrowings | $0.0m | $0.1m | −$0.0m |
| Payout ratio vs NPAT | 0.0% | — | — |
| Payout ratio vs FCF pre-lease | 0.0% | — | covered |
| ROE (annualised) | -16.1% | -13.8% | Weakening |
| HY22 share of FY22 revenue | 43.4% | — | Other half was 56.6% |
| HY22 share of FY22 NPAT | 66.4% | — | Other half was 33.6% |
| Profit from continuing operations | −$1.7m | −$1.8m | +$0.1m |
Reference: annolyse.ai/briefings/blt-hy23
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX/ASX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.